Search

We defined the pregnancy exposed to biological drugs if the woman had at least one administration during pregnancy: we identified 14 pregnancies in 12 women. Only one woman, after discontinuation of treatment with infliximab biosimilar, because of a very severe form of psoriasis and psoriatic arthritis, resumed the therapy and started certolizumab pegol, and continued during all pregnancies. Data available regarding pregnancy occurred in mother treated with secukinumab provide reassurance in cases of conception in mother exposed, because there is no evidence of adverse pregnancy outcomes.[7] No data are available for ixekizumab in pregnancy. [Extracted from the article]

Examination showed a very uneven repigmented leukoderma, with light brown and dark brown macules interspersed with depigmented macules (Fig. Piebaldism is characterized by congenital poliosis (white hair) and leukoderma (patches of white skin), mainly located on the scalp, mid-forehead, anterior trunk and central extremities. Another hypothesis is that non-static piebaldism might result from the digenic co-inheritance of the given KIT mutation and unknown dominant-acting unlinked mutation responsible for progressive or regressive pigmentation after birth.3,4 Acknowledgement The patients in this manuscript have given written informed consent to publication of their case details. [Extracted from the article]

Corrigendum: Sunshine on "Zebra People" Reference 1 Cortelazzi C, De Felici Del Giudice MB, Pierobon E, Pellacani G, Di Nuzzo S. Sunshine on "Zebra People". I J i I Eur Acad Dermatol Venereol i 2021; B 35 b : e308-e352. https://doi.org/10.1111/jdv.17088 In the version of this article initially published,1 the title of the article was 'Sunshine on "Zebra People"' which should be corrected as "Piebaldism: sunshine on Zebra People". [Extracted from the article]

A letter to the editor is presented that discusses side predominance of squamous cell carcinoma.

Dimethyl fumarate (DMF) is a fumaric acid esters derivate approved for plaque psoriasis as first-line systemic therapy. It has been available in Italy since 2017 and an increasing number of patients are treated with this drug. To evaluate DMF effectiveness, side effects and drug survival in a dermatological real-life setting. We performed a retrospective multi-center study in five dermatologic clinics in Emilia-Romagna, Northern Italy, which included all consecutive patients affected by moderate-severe psoriasis treated with DMF. We assessed effectiveness (in terms of PASI50 and PASI75 in an intention to treat observation) and safety (occurrence of side effects) of DMF and their association with demographic and disease characteristics, mean daily dose taken and treatment discontinuation. We included 103 patients, 78 (75.72%) had at least one comorbidity including 19 (18.44%) with a history of cancer; the mean treatment duration was 23.61 ± 17.99 weeks (min 4, max 130) and the mean daily dose was 262.13 ± 190.94 mg. Twenty-four patients (23.30%) reached PASI75 at week 12, while a further 18 patients (17.47%) reached it at week 26. Side effects occurred in 63 patients (61.16%), the most frequent were diarrhea, epigastric discomfort, nausea, and flushing. Sixteen patients (15.53%) showed an alteration of laboratory tests. In some cases side effects were transitory, while in 53 patients (51.45%) they led to cessation of therapy. The median daily dose showed a direct association with PASI50 achievement and an indirect association with treatment discontinuation. Our study shows the peculiarities of DMF in a real-world setting: effectiveness is often reached after 12 weeks of treatment and side effects could limit the continuation of the therapy but, at the same time, DMF has no major contraindications and, due to the wide range of dosage, it can allow both to manage side effects and to personalize the prescription for each patient., (© 2021 The Authors. Dermatologic Therapy published by Wiley Periodicals LLC.)

Background: Few and small studies have described the management of immunomodulant/immunosuppressive therapies or phototherapy in atopic dermatitis (AD) patients during coronavirus disease 2019 (COVID-19) pandemic., Methods: A national registry, named DA-COVID-19 and involving 35 Italian dermatology units, was established in order to evaluate the impact of COVID-19 pandemic on the management of adult AD patients treated with systemic immunomodulant/immunosuppressive medications or phototherapy. Demographic and clinical data were obtained at different timepoints by teledermatology during COVID-19 pandemic, when regular visits were not allowed due to sanitary restrictions. Disease severity was assessed by both physician- and patient-reported assessment scores evaluating itch intensity, sleep disturbances, and AD severity., Results: A total of 1831 patients were included, with 1580/1831 (86.3%) continuing therapy during pandemic. Most patients were treated with dupilumab (86.1%, 1576/1831) that was interrupted in only 9.9% (156/1576) of cases, while systemic immunosuppressive compounds were more frequently withdrawn. Treatment interruption was due to decision of the patient, general practitioner, or dermatologist in 39.9% (114/286), 5.6% (16/286), and 30.1% (86/286) of cases, respectively. Fear of increased susceptibility to SARS-CoV-2 infection (24.8%, 71/286) was one of the main causes of interruption. Sixteen patients (0.9%) resulted positive to SARS-CoV-2 infection; 3 of them (0.2%) were hospitalized but no cases of COVID-related death occurred., Conclusions: Most AD patients continued systemic treatments during COVID pandemic and lockdown period, without high impact on disease control, particularly dupilumab-treated patients., (© 2021 EAACI and John Wiley and Sons A/S. Published by John Wiley and Sons Ltd.)

Bexarotene is approved for the treatment of cutaneous T cell lymphomas in patients refractory to at least one prior systemic therapy. Associated hypertriglyceridaemia requires monitoring, but can readily be managed with concomitant medication, such as fenofibrate. Here we report three cases of hypertriglyceridaemia secondary to bexarotene assumption, which was adequately managed with omega-3 fatty acids. If fenofibate-related side effects occur, or a statin is required to control low-density lipoprotein-cholesterol, omega-3 fatty acids should be considered as a good alternative therapy to lower lipid levels during bexarotene treatment.